This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Abeona Therapeutics, Inc.
Drug Names(s): EB101, EB 101, LZRSE-COL7A1
Description: EB-101 is an ex vivo gene therapy used to prepare type VII collagen gene-corrected skin grafts. The inherited disease, dystrophic epidermolysis bullosa, is caused by recessive or dominant mutations in COL7A1, the gene encoding type VII collagen.
Additional information available to subscribers only: